English
Język Polski
A financial perspective on the pharmaceutical industry
Yunus Emre Kahraman
Yılmaz Çalışkan
Abstract
As a result of the epidemics in the world in recent years the importance of the health sector has once again emerged and countries have started to invest more in the health sector. In addition to developed countries, underdeveloped and developing countries are investing more in the health sector and technology and governments are trying to control increasing health expenditures. One of the important and dynamic sub-sectors of the health sector is the pharmaceutical sector. States and international companies are investing more in the pharmaceutical sector in order to combat the epidemics in recent years and are conducting more R&D studies by utilizing the developing technology. In this study in the light of the data published by the OECD, it is examined whether there is a similar relationship between the change in the share of health expenditures in the GNP (Gross National Product) of OECD countries between 2010 and 2022 and the change in the size of the pharmaceutical sector in OECD countries. The change in the size of the pharmaceutical sector and the change in the share of health expenditures in GNP have not yielded similar results in each OECD country. It is thought that different factors such as demographic characteristics, geographical location and economic conditions of countries should be taken into consideration when evaluating the relationship between these two variables.
Keywords:
Pharmaceuticals, Public Health, Finance, Financial MarketsSimilar Articles
- Aleksandra Białczyk, Gabriela Leśniak, Filip Nadolny, Justyna Mrowiec, Antoni Otałęga, Exploring digital health horizons: a narrative review of e-health innovations in Poland, Spain, Romania and Estonia. , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)
- Magdalena Makarewicz, Anna Łysiak, Katarzyna Łysiak, Barbara Maziarz, Evaluation of the effectiveness of platelet-rich plasma therapy in the treatment of osteoarthritis compared to other treatment methods , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
- Maciej Bara, Jakub Starownik, Jakub Szydło, Patryk Gryszkiewicz, Jakub Nieznański, Dapagliflozin - new solution in chronic kidney disease treatment , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
- Ewelina Flegiel, Magdalena Piotrowska, Magdalena Ptasznik, Aleksandra Baran, Justyna Lenart, Miłosz Podrażka, Joanna Mazurek, Hubert Stachowicz, Weronika Bartos, Monika Adamczyk, Review of the effects of sodium butyrate on obesity, inflammatory bowel disease, pregnancy and colorectal cancer , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
- Katarzyna Łysiak, Anna Łysiak, Barbara Maziarz, Paulina Przywara, Natalia Bogumiłło, Julia Ignacak, Kinga Ściurka, Mikołaj Borek, Oliwia Grzelak, Insomnia in the elderly and contemporary treatment methods , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
- Dominika Winiarz, Kamila Domańska, Kinga Paluch, Dorota Dorota Skrajnowska, PROBIOTICS AND HEALTH - TODAY AND TOMORROW , Prospects in Pharmaceutical Sciences: Vol. 15 No. 10 (2017)
- Katarzyna Kozon, Małgorzata Krzyżanowska, Jakub Olszewski, Andrzej Patyra, Spinal muscular atrophy – the effectiveness of treatment and new therapeutic possibilities for selected groups of patients in Poland , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
- Małgorzata Krzyżanowska, Katarzyna Kozon, Jakub Olszewski, Andrzej Patyra, Efficacy of satralizumab therapy in the treatment of NMOSD , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
- Daria Żuraw, Paulina Oleksa, Mateusz Sobczyk, Kacper Jasiński, Simple obesity in children , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
- Agnieszka Kalicka, Natalia Tarłowska, Counterfeit and illegal medicinal products as an example of drugs that do not meet the basic quality requirements , Prospects in Pharmaceutical Sciences: Vol. 21 No. 4 (2023)
You may also start an advanced similarity search for this article.
Details
References
Statistics
Authors
Citation rules
Cited by / Share
Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.